Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse

Nutrition and Diabetes

Volumn 7, Issue 4, 2017, Pages

  Carbone, S ^a,b   Lee, P J H ^a   Mauro, A G ^a   Mezzaroma, E ^a   Buzzetti, R ^b   Van Tassell, B ^a   Abbate, A ^a   Toldo, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART CATHETERIZATION; HEART DISEASE; HEART LEFT VENTRICLE DIASTOLIC FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SYSTOLIC FUNCTION; HEART PERFORMANCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WESTERN DIET; ANIMAL; BLOOD; C57BL MOUSE; CALORIC INTAKE; CARDIAC MUSCLE; COMPLICATION; DIABETES MELLITUS; DIASTOLE; EATING; FAT INTAKE; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SUGAR INTAKE; SYSTOLE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIASTOLE; DIET, WESTERN; DIETARY FATS; DIETARY SUGARS; EATING; ECHOCARDIOGRAPHY, DOPPLER; ENERGY INTAKE; HEART FAILURE; HEART VENTRICLES; HYPERGLYCEMIA; INFLAMMATION; INTERLEUKIN-18; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; OBESITY; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 85017362411     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2017.1     Document Type: Article

References (26)

1. Carbone S, Mauro AG, Mezzaroma E, Kraskauskas D, Marchetti C, Buzzetti R, et al. A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. Int J Cardiol 2015; 198: 66-69.
2. Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation 2013; 128: 1910-1923.
3. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 119-129.
4. O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014; 20: 221-229.
5. Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Hear Circ Physiol 2014; 306: 1025-1031.
6. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT-H, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
7. Reynolds CM, McGillicuddy FC, Harford KA, Finucane OM, Mills KHG, Roche HM. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res 2012; 56: 1212-1222.
8. Li X, Du N, Zhang Q, Li J, Chen X, Liu X, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis 2014; 5: E1479.
9. Collino M, Benetti E, Rogazzo M, Mastrocola R, Yaqoob MM, Aragno M, et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR- A gonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol 2013; 85: 257-264.
10. Stienstra R, Joosten LAB, Koenen T, van Tits B, van Diepen JA, van den Berg SAA, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12: 593-605.
11. L'homme L, Esser N, Riva L, Scheen A, Paquot N, Piette J, et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res 2013; 54: 2998-3008.
12. Sui Y-H, Luo W-J, Xu Q-Y, Hua J. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. World J Gastroenterol 2016; 22: 2533-2544.
13. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650-656.
14. Carbone S, Shah KB, Van Tassell B, JMJ Canada, Evans RK, Regan JA, et al. Obesity and diastolic heart failure: Is inflammation the link Transl Med 2013; 3: E124.
15. Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
16. Mcgillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KHG, et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011; 60: 1688-1698.
17. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003; 198: 877-888.
18. Coll RC, LAJO Neill, Schroder K. Questions and controversies in innate immune research : What is the physiological role of NLRP3 Nat Publ Gr 2016; 1-5.
19. Kitzman DW, Shah SJ. The HFpEF obesity phenotype: The elephant in the room. J Am Coll Cardiol 2016; 68: 200-203.
20. Carbone S, Canada JM, Buckley L, Trankle CR, Dixon DL, Buzzetti R, et al. Obesity contributes to exercise intolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2016; 68: 2487-2488.
21. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013; 1: 93-102.
22. Carbone S, Lavie CJ, Arena R, et al. Obesity and Heart Failure: Focus on the Obesity Paradox. Mayo Clinic Proceedings 2017. In press. Available at: Http://dx. doi. org/10. 1016/j. mayocp. 2016. 11. 001
23. Regan JA, Mauro AG, Carbone S, Marchetti C, Mezzaroma E, Krauskaus D, et al. Interleukin-18 blockade prevents diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction. Circulation 2015; 132: A14648-A14648.
24. McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, et al. A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One 2016; 11: E0150018.
25. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 31: 109-116.
26. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. AJP Heart Circ Physiol 2011; 301: H2181-H2190.